Physician profile
Peter M Browne
NPI 1730156670
$7,027.32
in general payments reported to CMS, 2019-2025
38 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $741 · 2021: $850 · 2022: $1,278 · 2023: $1,575 · 2024: $855 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.00 |
| Education | $217.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,464.98 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Harmony Biosciences LLC | $1,102.85 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.09 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $425.69 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Grifols USA, LLC | $335.38 | 2019-2025 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $263.60 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $239.26 | 2021-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $223.26 | 2019-2022 | |
| Insmed, INC. | $180.82 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $176.78 | 2019-2023 | Yupelri |
| Genzyme Corporation | $175.37 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $159.31 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Ucb, INC. | $150.50 | 2019-2021 | |
| United Therapeutics Corporation | $114.99 | 2023-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $107.30 | 2020-2024 | Acthar |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $102.44 | 2023-2025 | Sunosi |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Baxter Healthcare | $87.88 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $85.90 | 2021-2024 | Smartvest |
| Pulmonx Corporation | $82.13 | 2022-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Phadia US INC. | $78.02 | 2021-2024 | Immunocap |
| Bausch Health US, LLC | $65.57 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $62.70 | 2023-2024 | Lumryz |
| Genentech USA, INC. | $62.49 | 2019 | |
| Verona Pharma, INC. | $45.40 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $45.15 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $41.23 | 2020-2022 | |
| Viatris Specialty LLC | $40.86 | 2025 | Yupelri |
| Lilly USA, LLC | $40.39 | 2020-2025 | Zepbound |
| Vanda Pharmaceuticals INC. | $39.18 | 2019-2023 | Hetlioz |
| Mallinckrodt Enterprises LLC | $33.91 | 2019 | |
| La Jolla Pharmaceutical Company | $28.40 | 2023 | Giapreza |
| Gilead Sciences, INC. | $25.32 | 2022 | |
| Ani Pharmaceuticals, INC. | $22.50 | 2024 | Purified Cortrophin Gel |
| Philips North America LLC | $18.45 | 2025 | Vest Therapy Und |
| Sanofi Pasteur INC. | $17.42 | 2019 | |
| Seqirus USA INC | $15.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.